This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also […]
This is an early-phase clinical trial testing a new drug called BI-1607 for people with melanoma that has spread or cannot be removed by surgery. The aim is to see whether combining BI-1607 with two existing treatments, ipilimumab and pembrolizumab, is safe and more effective than current options. BI-1607 is designed to help the body’s
This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.
This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity
Study of Roginolisib in UM Patients (OCULE-01) Read More »
This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a
Study of RP-3500, Camonsertib, in Advanced Solid Tumors Read More »
This is the first trial in humans to test T3P-Y058-739, a genetically modified and weakened strain of the bacterium Yersinia enterocolitica. The study aims to find the right dose, test its safety, and see how well it works in people with advanced solid tumours.
First in Human Study of T3P-Y058-739 (T3P) Read More »
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Read More »
This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.
Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Read More »
